Page 123 - 202010

2010，363（10）：930-942. cagrelor compared with clopidogrel in Chinese elderly pa-
[ 5 ] LEVINE GN，JEONG Y，GOTO S，et al. World heart fed- tients with acute coronary syndrome[J]. Ther Clin Risk
eration expert consensus statement on antiplatelet therapy Manag，2016. DOI：10.2147/TCRM.S108965.
in east Asian patients with ACS or undergoing PCI[J]. Nat [16] MIYAZAKI Y，SUWANNASOM P，SOTOMI Y，et al.
Rev Cardiol，2014，11（10）：597-606. Single or dual antiplatelet therapy after PCI[J]. Nat Rev
[ 6 ] BONACA MP，BHATT DL，COHEN M，et al. Long-term Cardiol，2017，14（5）：294-303.
use of ticagrelor in patients with prior myocardial infarc- [17] FRANCHI F，ANGIOLILLO DJ. Novel antiplatelet ag-
tion[J]. N Engl J Med，2015，372（19）：1791-1800. ents in acute coronary syndrome[J]. Nat Rev Cardiol，
[ 7 ] WALLENTIN L，BECKER RC，BUDAJ A，et al. Ticagre- 2015，12（1）：30-47.
lor versus clopidogrel in patients with acute coronary syn- [18] CHEN Y，DONG W，WAN Z，et al. Ticagrelor versus clop-
dromes[J]. N Engl J Med，2009，361（11）：1045-1057. idogrel in Chinese patients with acute coronary syndrome：
[ 8 ] CAPODANNO D，ALFONSO F，LEVINE GN，et al. a pharmacodynamic analysis[J]. Int J Cardiol，2015. DOI：
ACC/AHA versus ESC guidelines on dual antiplatelet 10.1016/j.ijcard.2015.06.030.
therapy[J]. J Am Coll Cardiol，2018，72（23）：2915-2931. [19] 韩雅玲.替格瑞洛临床应用中国专家共识[J].临床军医杂
[ 9 ] JEONG YH.“East asian paradox”：challenge for the cur- 志，2016，44（5）：444-453.
rent antiplatelet strategy of“one-guideline-fits-all races” [20] 胡盛寿，高润霖，刘力生，等.《中国心血管病报告 2018》
in acute coronary syndrome[J]. Curr Cardiol Rep，2014. 概要[J].中国循环杂志，2019，34（3）：209-220.
DOI：10.1007/s11886-014-0485-4. [21] TANTRY US，BONELLO L，ARADI D，et al. Consensus
[10] GOTO S，HUANG CH，PARK SJ，et al. Ticagrelor vs. and update on the definition of on-treatment platelet reac-
clopidogrel in Japanese，Korean and Taiwanese patients tivity to adenosine diphosphate associated with ischemia
with acute coronary syndrome：randomized，double-blind， and bleeding[J]. J Am Coll Cardiol，2013，62（24）：2261-
phase Ⅲ PHILO study[J]. Circ J，2015，79（11）： 2273.
2452-2460. [22] SCOTT SA，SANGKUHL K，STEIN CM，et al. Clinical
[11] 谷鸿秋，王杨，李卫. Cochrane 偏倚风险评估工具在随机 pharmacogenetics implementation consortium guidelines
对照研究 Meta 分析中的应用[J].中国循环杂志，2014， for CYP2C19 genotype and clopidogrel therapy：2013 up-
29（2）：147-148. date[J]. Clin Pharmacol Ther，2013，94（3）：317-323.
[12] CHEN IC，LEE CH，FANG CC，et al. Efficacy and safety [23] CALCAGNO S，LUCISANO L，MANCONE M，et al.
of ticagrelor versus clopidogrel in acute coronary syn- Bleeding versus thrombosis：role of short DAPT in com-
drome in Taiwan：a multicenter retrospective pilot stu- plex lesions[J]. Minerva Cardioangiol，2015，63（6）：
dy[J]. J Chin Med Assoc，2016，79（10）：521-530. 533-546.
[13] KANG HJ，CLARE RM，GAO R，et al. Ticagrelor versus [24] KWON TJ，TANTRY US，PARK Y，et al. Influence of
clopidogrel in Asian patients with acute coronary syn- platelet reactivity on BARC classification in east Asian pa-
drome：a retrospective analysis from the platelet inhibition tients undergoing percutaneous coronary intervention：re-
and patient outcomes （PLATO） trial[J]. Am Heart J， sults of the ACCEL-BLEED study[J]. Thromb Haemost，
2015，169（6）：899-905. 2016，115（5）：979-992.
[14] PARK KH，JEONG MH，AHN Y，et al. Comparison of [25] YUN JE，KIM YJ，PARK JJ，et al. Safety and effective-
short-term clinical outcomes between ticagrelor versus ness of contemporary P2Y12 inhibitors in an east Asian
clopidogrel in patients with acute myocardial infarction population with acute coronary syndrome：a nationwide
undergoing successful revascularization：from Korea Acu- population-based cohort study[J]. J Am Heart Assoc，
te Myocardial Infarction Registry-National Institute of 2019. DOI：10.1161/JAHA.119.012078.
Health[J]. Int J Cardiol，2016. DOI：10.1016/j.ijcard.2016. （收稿日期：2019-10-08 修回日期：2020-03-27）
04.044. （编辑：陈 宏）
[15] WANG H，WANG X. Efficacy and safety outcomes of ti-

《中国药房》杂志——中国科技核心期刊，欢迎投稿、订阅

中国药房 2020年第31卷第10期 China Pharmacy 2020 Vol. 31 No. 10 ·1265 ·